Globocan	Global Burden of Cancer Study
LVEF	Left Ventricular Ejection Fraction
QoL	Quality of Life
WHO	World Health Organization
ASIR	Age-Standardized Incidence Rate
ER	Estrogen Receptor
PR	Progesterone Receptor
HER2	Human Epidermal Growth Factor Receptor 2
TNBC	Triple-Negative Breast Cancer
ASCO	American Society of Clinical Oncology
DFS	Disease-Free Survival
OS	Overall Survival
NOAH	Neoadjuvant Herceptin
EFS	Event-Free Survival
IDFS	Invasive Disease-Free Survival
T-DM1	Trastuzumab Emtansine
pCR	Pathologic Complete Response
ASE	American Society of Echocardiography
EACVI	European Society of Cardiovascular Imaging
ESC	European Society of Cardiology
CTRCD	Cancer Therapy-Related Cardiovascular Dysfunction
EF	Ejection Fraction
GLS	Global Longitudinal Strain
cTn	Cardiac Troponin
hs-cTn	High-Sensitivity Cardiac Troponin
TIC	Trastuzumab-Induced Cardiotoxicity
ROS	Reactive Oxygen Species
TOP2B	Topoisomerase II Beta
dsDNA	Double-Strand DNA
SQ-DOX	Semiquinone Doxorubicin
O2•−	Superoxide Anions
H2O2	Hydrogen Peroxide
SOD	Superoxide Dismutase
OH•	Hydroxyl Radicals
TRZ	Trastuzumab
NRG1	Neuregulin-1
NO	Nitric Oxide
MAPK	Mitogen-Activated Protein Kinase
PI3K	Phosphoinositide 3-Kinases
mPTP	Mitochondrial Permeability Transition Pores
HFA	Heart Failure Association
ICOS	International Cardio-Oncology Society
CRT-CVT	Cardiovascular Toxicity Associated with Cancer Treatment
ECG	Electrocardiogram
NPs	Natriuretic Peptides
ACEi	Angiotensin-Converting Enzyme Inhibitor
ARB	Angiotensin Receptor Blocker
RAAS	Renin–Angiotensin–Aldosterone System
FDA	Food and Drug Administration
AIC	Anthracycline-Induced Cardiomyopathy